- Home
- NEGG vs MOLN Comparison
NEGG vs MOLN Comparison
Compare NEGG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- MOLN
- Stock Information
- Founded
- NEGG 2001
- MOLN 2004
- Country
- NEGG United States
- MOLN Switzerland
- Employees
- NEGG N/A
- MOLN N/A
- Industry
- NEGG Other Specialty Stores
- MOLN
- Sector
- NEGG Consumer Discretionary
- MOLN
- Exchange
- NEGG Nasdaq
- MOLN Nasdaq
- Market Cap
- NEGG 122.3M
- MOLN 136.1M
- IPO Year
- NEGG 2010
- MOLN 2021
- Fundamental
- Price
- NEGG $15.70
- MOLN $3.71
- Analyst Decision
- NEGG
- MOLN
- Analyst Count
- NEGG 0
- MOLN 0
- Target Price
- NEGG N/A
- MOLN N/A
- AVG Volume (30 Days)
- NEGG 1.3M
- MOLN 2.4K
- Earning Date
- NEGG 04-28-2025
- MOLN 08-25-2025
- Dividend Yield
- NEGG N/A
- MOLN N/A
- EPS Growth
- NEGG N/A
- MOLN N/A
- EPS
- NEGG N/A
- MOLN N/A
- Revenue
- NEGG $1,235,576,000.00
- MOLN $2,525,030.00
- Revenue This Year
- NEGG N/A
- MOLN N/A
- Revenue Next Year
- NEGG N/A
- MOLN $866.67
- P/E Ratio
- NEGG N/A
- MOLN N/A
- Revenue Growth
- NEGG N/A
- MOLN N/A
- 52 Week Low
- NEGG $3.32
- MOLN $3.36
- 52 Week High
- NEGG $26.40
- MOLN $12.22
- Technical
- Relative Strength Index (RSI)
- NEGG 67.46
- MOLN 51.23
- Support Level
- NEGG $9.85
- MOLN $3.58
- Resistance Level
- NEGG $14.02
- MOLN $3.86
- Average True Range (ATR)
- NEGG 1.99
- MOLN 0.16
- MACD
- NEGG 0.33
- MOLN 0.01
- Stochastic Oscillator
- NEGG 76.82
- MOLN 50.79
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.